Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Inclusion Criteria: * At least two pathogenic mutations of ATP-Binding Cassette (ABC)A4 gene confirmed by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory * Best corrected visual acuity in the study eye between 20/20 - 20/200 Snellen equivalent, inclusive Exclusion Criteria: * Macular atrophy secondary to any condition other than STGD1 in either eye * Any prior treatment for STGD1 including gene therapy, stem cell therapy or any prior intravitreal treatment for any indication in either eye * Participation in an interventional study of a vitamin A derivative \</= 3 months prior to screening * Presence of intraocular inflammation, macular hole, pathologic myopia, epiretinal membrane, evidence of significant vitreo-macular traction, vitreous hemorrhage or aphakia * Any intraocular surgery or thermal laser within 3 months of trial entry. Any prior thermal laser in the macular region * Diabetes mellitus * Hemoglobin A1c (HbA1c) value of \>/=6.5% * Stroke within 12 months of trial entry * Any major surgical procedure within one month of trial entry or anticipated during the trial * Any treatment with an investigational agent in the past 60 days for any condition * Women who are pregnant or nursing * Known serious allergies to the fluorescein dye used in angiography, povidone iodine, or to the components of the avacincaptad pegol formulation